Takeda Funds Celiac Asset As Prelude To Potential Acquisition
Takeda has started off the new year by continuing down the path of partnerships to strengthen its core therapeutic areas, this time linking up with a US academic spin-out for a potential oral therapy for celiac disease.
You may also be interested in...
Under Momenta/CSL autoimmune partnership, Momenta can opt in to co-development or commercialization on recombinant Fc receptor modulator or just earn a revenue stream from CSL’s efforts with the preclinical candidate. Pieris and Servier sign broad-based immuno-oncology collaboration, while Arena hands off the disappointing Belviq to Eisai.
Deals with TiGenix and Altos add to a growing gastrointestinal pipeline, as the Japanese pharma sees Entyvio and GI, not Velcade and cancer, as its primary growth-driver.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.